[NEW YORK] – Nuvation Bio Inc., a clinical-stage biopharmaceutical company focused on oncology, announced a landmark financing agreement with Sagard Healthcare Partners, securing up to $250 million in non-dilutive capital to accelerate its drug development pipeline. This transaction, comprising a mix of royalty and revenue interest financing, provides Nuvation Bio with immediate and potential future funds to advance its innovative cancer therapies, particularly its lead candidates targeting solid tumors, without diluting shareholder equity.
The financing package includes an initial tranche with the flexibility for additional draws, structured to align with Nuvation Bio’s clinical milestones and revenue potential. This capital injection bolsters the company’s efforts to progress its oncology portfolio, including novel small molecule inhibitors designed to address unmet needs in cancer treatment, building on its robust research and development framework. Sagard Healthcare Partners, a division of Sagard, brings its expertise in healthcare investment to this partnership, reinforcing Nuvation Bio’s financial stability as it navigates the costly phases of clinical trials and regulatory approval.
This non-dilutive approach preserves Nuvation Bio’s ownership structure, a critical advantage for a middle-market biotech aiming to maintain control while scaling operations. The deal reflects growing confidence in Nuvation Bio’s pipeline, which targets high-value oncology markets projected to grow significantly through 2025, amid rising demand for precision medicine solutions. For Sagard Healthcare Partners, this investment aligns with its strategy of supporting transformative healthcare companies, leveraging royalty-based financing to share in future revenue streams without equity stakes. The transaction positions Nuvation Bio to expedite its clinical programs, potentially accelerating timelines for bringing therapies to patients in need. Read the full announcement here.
